Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT05033743

Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

Sponsor: Indiana University

Conditions Recurrent Bacterial Vaginosis

Interventions Secnidazole 2 GM Oral Granules

Updated 6 times since 2021 Last updated: Feb 2, 2024 Started: Jul 9, 2021 Primary completion: Oct 7, 2022 Completion: Oct 7, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Recurrent Bacterial Vaginosis, this trial is completed. The trial is conducted by Indiana University and has accumulated 6 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Mar 2024 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2023 — Mar 2024 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed
Apr 2022 — Jun 2023 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Oct 2021 — Apr 2022 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Indiana University
Lupin Pharmaceuticals, Inc.

Data source: Indiana University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States